clinical trial · NCT06801834
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Gilead Sciences·phase3·recruiting·n = 695
Extensive Stage Small Cell Lung Cancer (ES-SCLC)Sacituzumab Govitecan (SG)TopotecanAmrubicin (Japan only)
brief summary
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (ES-SCLC). The primary objectives of this study are to compare the effect of SG to SOC on objective response rate (ORR) as assessed by blinded independent central review (BICR) according to the Response Evaluation Criteria in Solid Tumors and to compare the effect of SG to SOC on overall survival (OS).
started
Apr 4, 2025
primary completion
Oct 1, 2029
completion
Oct 1, 2029
last updated
Mar 19, 2026
official title
A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol